Charles River Laboratories International, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $213.8M | $194.6M | $276.8M | $233.9M | $241.2M | $228.4M | $238.0M | $195.4M |
| Accounts Receivable | $708.9M | $720.9M | $780.4M | $752.4M | $642.9M | $617.7M | $514.0M | $472.2M |
| Inventory | $299.1M | $278.5M | $380.3M | $255.8M | $199.1M | $185.7M | $160.7M | $127.9M |
| Total Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $897.8M |
| Property, Plant & Equipment | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $909.4M |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B |
| Intangible Assets (Excl. Goodwill) | $340.0M | $723.4M | $864.1M | $955.3M | $1.06B | $787.6M | $689.4M | $610.9M |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B |
| Liabilities | ||||||||
| Accounts Payable | $148.8M | $140.3M | $168.9M | $205.9M | $198.1M | $122.5M | $111.5M | $66.3M |
| Total Current Liabilities | $1.12B | $994.1M | $1.06B | $1.09B | $1.03B | $839.8M | $710.2M | $558.2M |
| Long-Term Debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B | $1.93B | $1.85B | $1.61B |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $980.8M | $625.4M | $280.3M | $42.1M |
| Total Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B |